Patents by Inventor Sandip Panicker

Sandip Panicker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF INDUCING COMPLEMENT ACTIVITY
    Publication number: 20200239556
    Abstract: The present disclosure provides methods of inducing a complement activity on a surface of a cell comprising contacting the cell with an effective amount of an anti-Factor B antibody, wherein the anti-Factor B antibody inhibits dissociation of a C3bBb complex into a Factor Bb and a C3b.
    Type: Application
    Filed: October 11, 2018
    Publication date: July 30, 2020
    Applicant: Bioverativ USA Inc.
    Inventors: Sandip Panicker, Stephen Moore, Pavel A. Nikitin, Tony Byun, Graham Parry
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20200079875
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: September 5, 2019
    Publication date: March 12, 2020
    Applicant: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20200079876
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: September 18, 2019
    Publication date: March 12, 2020
    Applicant: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200048332
    Abstract: The present disclosure provides antibodies that specifically bind complement pathway component C1s. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the anti-C1s antibodies. The present disclosure provides methods of use of the anti-C1s antibodies.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 13, 2020
    Applicant: Bioverativ USA Inc.
    Inventors: Sandip Panicker, Graham Parry, Nancy E. Stagliano
  • Anti-complement C1s antibodies
    Patent number: 10457745
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 29, 2019
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Anti-complement C1s antibodies
    Patent number: 10450382
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 22, 2019
    Assignee: Bioverativ USA Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
    Publication number: 20190153079
    Abstract: The present disclosure provides anti-complement factor Bb antibodies, and compositions comprising the antibodies. The anti-Bb antibodies are useful for treating complement-mediated disorders. The present disclosure provides methods of treating complement-mediated disorders.
    Type: Application
    Filed: April 3, 2017
    Publication date: May 23, 2019
    Applicant: Bioverativ USA Inc.
    Inventors: Sandip Panicker, Graham Parry, Karen Sue Christopherson, Tony SangYoung Byun
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20170226229
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: December 20, 2016
    Publication date: August 10, 2017
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20170226230
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: December 20, 2016
    Publication date: August 10, 2017
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Methods of inhibiting complement C4 activation with anti-complement C1s antibodies
    Patent number: 9562092
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: February 7, 2017
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Anti-complement C1s antibodies and methods of inhibiting complement C1s activity
    Patent number: 9562106
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: February 7, 2017
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Anti-complement C1s antibodies and methods of inhibiting complement C1s activity
    Patent number: 9512233
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: December 6, 2016
    Assignee: True North Therapeutics, Inc.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20160053002
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: November 4, 2015
    Publication date: February 25, 2016
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • CELL PENETRATING PEPTIDES WHICH BIND IRF5
    Publication number: 20160009772
    Abstract: The present invention comprises cell penetrating peptides that bind to interferon regulatory factor IRF5 and disrupt the IRF5 homo-dimerization and/or attenuate downstream signaling, and a method for screening peptides that inhibit IRF5. Generally, the cell penetrating peptides of the invention bind human interferon regulatory factor IRF5 (CPP-IRF5).
    Type: Application
    Filed: October 7, 2013
    Publication date: January 14, 2016
    Inventors: Julie Demartino, Nader Fotouhi, Ann Hoffman, Kuo-Sen Huang, Francesca Milletti, Sandip Panicker, Dinesh Srinivasan, Seng-Lai Tan
  • Methods of inhibiting complement C4 activation with anti-complement C1S antibodies
    Patent number: 9206259
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: December 8, 2015
    Assignee: TRUE NORTH THERAPEUTICS, INC.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20150329645
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: April 21, 2015
    Publication date: November 19, 2015
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20150307626
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: May 11, 2015
    Publication date: October 29, 2015
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
    Publication number: 20150259437
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: May 11, 2015
    Publication date: September 17, 2015
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Methods of inhibiting activation of complement component C4 with anti-C1s antibodies
    Patent number: 9074004
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: July 7, 2015
    Assignee: TRUE NORTH THERAPEUTICS, INC.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Methods of inhibiting activation of complement component C4 with anti-C1s antibodies
    Patent number: 9074003
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 7, 2015
    Assignee: TRUE NORTH THERAPEUTICS, INC.
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker